Voleon Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.69M Buy
64,106
+56,726
+769% +$3.26M 0.07% 264
2026
Q1
$448K Buy
7,380
+734
+11% +$42.8K 0.01% 595
2025
Q4
$358K Sell
6,646
-19,092
-74% -$918K 0.01% 642
2025
Q3
$1.16M Buy
25,738
+10,064
+64% +$470K 0.03% 409
2025
Q2
$726K Buy
+15,674
New +$769K 0.04% 276
2025
Q1
Sell
-37,313
Closed -$2.11M 338
2024
Q4
$2.11M Buy
+37,313
New +$2.08M 0.16% 135

Other funds holding BMY

Voleon Capital Management's BMY Position: Q2 2026 in Review

Voleon Capital Management increased its Bristol-Myers Squibb (BMY) stake by 769% in Q2 2026, buying an estimated $3.26M and bringing the position to 64,106 shares worth $3.69M. The position accounts for 0.07% of the portfolio, ranked #264.

Voleon Capital Management first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Voleon Capital Management held 64,106 shares of Bristol-Myers Squibb worth $3.69M as of Q2 2026.
  • Voleon Capital Management bought 56,726 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.26M.
  • Bristol-Myers Squibb made up 0.07% of Voleon Capital Management's portfolio in Q2 2026, its #264 holding.
  • Voleon Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.